Tryptophan/kynurenine metabolism in human leukocytes is independent of superoxide and is fully maintained in chronic granulomatous disease

Blood

Volumn 116, Issue 10, 2010, Pages 1755-1760

  De Ravin, Suk See ^a   Zarember, Kol A ^a   Long Priel, Debra ^b   Chan, King C ^c   Fox, Stephen D ^c   Gallin, John I ^a   Kuhns, Douglas B ^b   Malech, Harry L ^a  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

^c SAIC FREDERICK INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYBB PROTEIN, HUMAN; GAMMA INTERFERON; INDOLEAMINE 2,3 DIOXYGENASE; KYNURENINE; MEMBRANE PROTEIN; NEUTROPHIL CYTOSOLIC FACTOR 1; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; SUPEROXIDE; TRYPTOPHAN;

BLOOD; CELL CULTURE; CHRONIC GRANULOMATOUS DISEASE; CYTOLOGY; DEFICIENCY; DOSE RESPONSE; DRUG EFFECTS; ELECTROSPRAY MASS SPECTROMETRY; GENETICS; HUMAN; IMMUNOBLOTTING; KINETICS; LEUKOCYTE; LIQUID CHROMATOGRAPHY; METABOLISM; MONOCYTE; NEUTROPHIL; TIME; URINE;

CELLS, CULTURED; CHROMATOGRAPHY, LIQUID; DOSE-RESPONSE RELATIONSHIP, DRUG; GRANULOMATOUS DISEASE, CHRONIC; HUMANS; IMMUNOBLOTTING; INDOLEAMINE-PYRROLE 2,3,-DIOXYGENASE; INTERFERON-GAMMA; KINETICS; KYNURENINE; LEUKOCYTES; MEMBRANE GLYCOPROTEINS; MONOCYTES; NADPH OXIDASE; NEUTROPHILS; SPECTROMETRY, MASS, ELECTROSPRAY IONIZATION; SUPEROXIDES; TIME FACTORS; TRYPTOPHAN;

EID: 77956579626     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2009-07-233734     Document Type: Article

References (24)

1. Segal BH, Leto TL, Gallin JI, Malech HL, Holland SM. Genetic, biochemical, and clinical features of chronic granulomatous disease. Medicine (Baltimore). 2000;79(3):170-200. (Pubitemid 30327531)
2. Lekstrom-Himes JA, Kuhns DB, Alvord WG, Gallin JI. Inhibition of human neutrophil IL-8 production by hydrogen peroxide and dysregulation in chronic granulomatous disease. J Immunol. 2005;174(1):411-417.
3. Brown JR, Goldblatt D, Buddle J, Morton L, Thrasher AJ. Diminished production of anti-inflammatory mediators during neutrophil apoptosis and macrophage phagocytosis in chronic granulomatous disease (CGD). J Leukoc Biol. 2003;73(5):591-599.
4. Fuchs TA, Abed U, Goosmann C, et al. Novel cell death program leads to neutrophil extracellular traps. J Cell Biol. 2007;176(2):231-241.
5. Henderson WR, Klebanoff SJ. Leukotriene production and inactivation by normal, chronic granulomatous disease and myeloperoxidase-deficient neutrophils. J Biol Chem. 1983;258(22):13522-13527. (Pubitemid 14204552)
6. Jackson SH, Gallin JI, Holland SM. The p47phox mouse knock-out model of chronic granulomatous disease. J Exp Med. 1995;182(3):751-758.
7. Pollock JD, Williams DA, Gifford MA, et al. Mouse model of X-linked chronic granulomatous disease, an inherited defect in phagocyte superoxide production. Nat Genet. 1995;9(2):202-209.
8. Romani L, Fallarino F, De Luca A, et al. Defective tryptophan catabolism underlies inflammation in mouse chronic granulomatous disease. Nature. 2008;451(7175):211-215.
9. Hirata F, Hayaishi O. Studies on indoleamine 2,3-dioxygenase. I. Superoxide anion as substrate. J Biol Chem. 1975;250(15):5960-5966.
10. Romani L, Zelante T, De Luca A, Fallarino F, Puccetti P. IL-17 and therapeutic kynurenines in pathogenic inflammation to fungi. J Immunol. 2008;180(8):5157-5162.
11. Zelante T, Fallarino F, Bistoni F, Puccetti P, Romani L. Indoleamine 2,3-dioxygenase in infection: The paradox of an evasive strategy that benefits the host. Microbes Infect. 2009;11(1):133-141.
12. Werner ER, Bitterlich G, Fuchs D, et al. Human macrophages degrade tryptophan upon induction by interferon-gamma. Life Sci. 1987;41(3):273-280.
13. Narui K, Noguchi N, Saito A, et al. Anti-infectious activity of tryptophan metabolites in the L-tryptophan-L-kynurenine pathway. Biol Pharm Bull. 2009;32(1):41-44.
14. Pfefferkorn ER. Interferon gamma blocks the growth of Toxoplasma gondii in human fibroblasts by inducing the host cells to degrade tryptophan. Proc Natl Acad Sci U S A. 1984;81(3):908-912. (Pubitemid 14197611)
15. Kuhns DB. Assessment of Neutrophil Function. In: Rich R, Fleisher T, Kotzin B, Schroeder H, eds. Clinical Immunology. 3rd ed. London: Harcourt International; 2007:1461-1470.
16. Heeley AF, Heeley ME, Hardy J, Soothill JF. A disorder of tryptophan metabolism in chronic granulomatous disease. Arch Dis Child. 1970;45(242):485-490.
17. Taylor MW, Feng GS. Relationship between interferon- gamma, indoleamine 2,3-dioxygenase, and tryptophan catabolism. FASEB J. 1991;5(11):2516-2522.
18. Yoshida R, Imanishi J, Oku T, Kishida T, Hayaishi O. Induction of pulmonary indoleamine 2,3-dioxygenase by interferon. Proc Natl Acad Sci U S A. 1981;78(1):129-132.
19. Maghzal GJ, Thomas SR, Hunt NH, Stocker R. Cytochrome b5, not superoxide anion radical, is a major reductant of indoleamine 2,3-dioxygenase in human cells. J Biol Chem. 2008;283(18):12014-12025.
20. A controlled trial of interferon gamma to prevent infection in chronic granulomatous disease. The International Chronic Granulomatous Disease Cooperative Study Group. N Engl J Med. 1991;324(8):509-516.
21. Segal BH, Kuhns DB, Ding L, Gallin JI, Holland SM. Thioglycollate peritonitis in mice lacking C5, 5-lipoxygenase, or p47(phox): complement, leukotrienes, and reactive oxidants in acute inflammation. J Leukoc Biol. 2002;71(3):410-416.
22. Rajakariar R, Newson J, Jackson EK, et al. Nonresolving inflammation in gp91phox-/- mice, a model of human chronic granulomatous disease, has lower adenosine and cyclic adenosine 5′-monophosphate. J Immunol. 2009;182(5):3262-3269.
23. van de Veerdonk FL, Smeekens SP, Joosten LA, et al. Reactive oxygen species-independent activation of the IL-1beta inflammasome in cells from patients with chronic granulomatous disease. Proc Natl Acad Sci U S A. 107(7):3030-3033.
24. Kobayashi SD, Voyich JM, Braughton KR, et al. Gene expression profiling provides insight into the pathophysiology of chronic granulomatous disease. J Immunol. 2004;172(1):636-643.